Hepatic arterial infusion chemotherapy with cisplatin before radical local treatment of early hepatocellular carcinoma (JIS score 0/1) improves survival

• Published in: Annals of oncology Vol. 25; no. 7; pp. 1379 - 1384
• Main Authors: Ishikawa, T., Kubota, T., Abe, S., Watanabe, Y., Sugano, T., Inoue, R., Iwanaga, A., Seki, K., Honma, T., Yoshida, T.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01-07-2014; Oxford University Press
• Subjects: Antineoplastic agents; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - physiopathology; chemotherapy; cisplatin; Cisplatin - adverse effects; Cisplatin - therapeutic use; Gastroenterology. Liver. Pancreas. Abdomen; hepatic arterial infusion (HAI); hepatocellular carcinoma; Humans; Infusions, Intra-Arterial; Liver Neoplasms - drug therapy; Liver Neoplasms - physiopathology; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Medical sciences; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Pharmacology. Drug treatments; Prospective Studies; Survival Rate; Tumors; cisplatin; hepatic arterial infusion (HAI); chemotherapy; hepatocellular carcinoma; Antineoplastic agent; Hepatic artery; Hepatic disease; Hepatocellular carcinoma; Early stage; Malignant tumor; Survival; Cisplatin; Liver cancer; Alkylating agent; Chemotherapy; Score; Treatment; Perfusion; Digestive diseases; Cancer; Platinum II Complexes
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/annonc/mdu155

It has not yet been determined whether hepatic arterial infusion (HAI) chemotherapy improves survival in patients with early hepatocellular carcinoma (HCC). We evaluated the effectiveness of HAI with high-concentration cisplatin (DDP-H) for the treatment of HCC by comparing outcomes between patients who received HAI with DDP-H before radical local treatment of early-stage HCC [Japan Integrated Staging (JIS) score 0/1] and patients who did not receive HAI chemotherapy.
Survival was analyzed in 114 patients with early-stage HCC who underwent radical local treatment. The patients were divided into two groups: a HAI group (n = 79) who received DDP-H infusion into the whole liver via the proper hepatic artery, and a non-HAI group (n = 35) who did not receive HAI chemotherapy.
The cumulative survival rates at 1, 3, and 5 years were 77.4%, 69.2%, and 55.3% in the non-HAI group and 97.4%, 87.0%, and 84.4% in the HAI group, respectively. Survival time prolonged significantly in the HAI group compared with the non-HAI group (log-rank test: P = 0.023; generalized Wilcoxon test: P = 0.012) Multivariate analysis using the Cox proportional hazards model identified HAI with DDP-H as the most important factor affecting survival.
Whole-liver HAI with DDP-H before radical local treatment can improve the prognosis of patients with early-stage HCC.